The return of the IP securitisation
A $250 miliion securitisation of future royalties generated from a yet-to-be approved hepatitis C drug being developed by Vertex Pharmaceuticals has got the Financial Times quite excited. The deal, being arranged by Morgan Stanley, will see Johnson …
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.